drugset / Trial / NCT06811233
Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study
Phase 2
Recruiting
140 enrolled
M.D. Anderson Cancer Center
Congressionally Directed Medical Research Programs · collab
NaSingle-groupOpen-labelSupportive care
Summary
The goal of this clinical research study is to learn if metal detoxification (with calcium disodium edetate \[Ca-EDTA\] and dimercaptosuccinic acid \[DMSA\]) during standard therapy can help improve outcomes in patients with intermediate-risk, high-risk, or secondary AML compared to standard therapy alone. Researchers think lowering the level of metals found in the blood/bone marrow may help to control the disease and/or improve the response to chemotherapy.
Timeline
- Start
- 2025-05-08
- Primary completion
- 2029-08-31
- Completion
- 2031-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CaEDTA | Unknown | — | Intravenous |
| Subject | Succimer | Small molecule | — | Oral |
| Background | Magnesium Sulfate | Other / unclassified | — | Other |